scholarly journals Endoscopic Ultrasound-guided Transmural Drainage for Palliation of Malignant Distal Common Bile Duct Obstruction in Patients With an Inaccessible Papilla: Approaching the Tipping Point?

2016 ◽  
Vol 14 (7) ◽  
pp. 1020-1021
Author(s):  
Todd H. Baron ◽  
Ian S. Grimm
Keyword(s):  
Bile Duct ◽  
Common Bile Duct ◽  
Endoscopic Ultrasound ◽  
Tipping Point ◽  
Bile Duct Obstruction ◽  
Ultrasound Guided ◽  
Distal Common Bile Duct ◽  
Duct Obstruction ◽  
Common Bile Duct Obstruction ◽  
Transmural Drainage

scholarly journals Aspirin for metal stent in malignant distal common bile duct obstruction (AIMS): Study protocol for a multicenter randomized controlled trial

2019 ◽  
Author(s):  
Jin Ho Choi ◽  
Woo Hyun Paik ◽  
Min Su You ◽  
Kyong Joo Lee ◽  
Young Hoon Choi ◽  
...  
Keyword(s):  
Bile Duct ◽  
Common Bile Duct ◽  
Controlled Trial ◽  
Bile Duct Obstruction ◽  
Metal Stents ◽  
Metal Stent ◽  
Stent Patency ◽  
Distal Common Bile Duct ◽  
Duct Obstruction ◽  
Common Bile Duct Obstruction

Abstract Background Endoscopic retrograde biliary drainage (ERBD) is the treatment of choice for patients with malignant distal common bile duct (CBD) obstruction. Self-expandable metal stents (SEMS), which are commonly used in unresectable cases, have many clinical advantages, including longer stent patency. Although the expected patency of SEMS is around eight months, it has recently been reported that the duration of SEMS patency in patients using aspirin is prolonged. Our study therefore aims to confirm the effect of aspirin on SEMS patency. Methods This is an investigator-initiated, prospective, multicenter, double-blind, randomized placebo-controlled trial that will be conducted from November 2017 in four tertiary centers in South Korea. We intend to include in our study 184 adult (≥ 20 years) patients with malignant distal CBD obstruction for whom ERBD with SEMS was successfully performed. The patients will be randomly allocated to two groups, which will comprise patients who have either taken 100 mg aspirin or a placebo for six months after index ERBD. The primary outcome will be the rate of stent dysfunction, and the secondary outcomes will be the duration of patency, the rate of reintervention, and the occurrence of adverse events. Discussion The aspirin for metal stents in malignant distal common bile duct obstruction (AIMS) study will determine the efficacy of aspirin in maintaining metal stent patency in patients with malignant distal CBD obstructive.

scholarly journals Aspirin for metal stent in malignant distal common bile duct obstruction (AIMS): Study protocol for a multicenter randomized controlled trial

2019 ◽  
Author(s):  
Jin Ho Choi ◽  
Woo Hyun Paik ◽  
Min Su You ◽  
Kyong Joo Lee ◽  
Young Hoon Choi ◽  
...  
Keyword(s):  
Bile Duct ◽  
Common Bile Duct ◽  
Controlled Trial ◽  
Bile Duct Obstruction ◽  
Metal Stents ◽  
Metal Stent ◽  
Stent Patency ◽  
Distal Common Bile Duct ◽  
Duct Obstruction ◽  
Common Bile Duct Obstruction

Abstract Background Endoscopic retrograde biliary drainage (ERBD) is the treatment of choice for patients with malignant distal common bile duct (CBD) obstruction. Self-expandable metal stents (SEMS), which are commonly used in unresectable cases, have many clinical advantages, including longer stent patency. Although the expected patency of SEMS is around eight months, it has recently been reported that the duration of SEMS patency in patients using aspirin is prolonged. Our study therefore aims to confirm the effect of aspirin on SEMS patency. Methods This is an investigator-initiated, prospective, multicenter, double-blind, randomized placebo-controlled trial that will be conducted from November 2017 in four tertiary centers in South Korea. We intend to include in our study 184 adult (≥ 20 years) patients with malignant distal CBD obstruction for whom ERBD with SEMS was successfully performed. The patients will be randomly allocated to two groups, which will comprise patients who have either taken 100 mg aspirin or a placebo for six months after index ERBD. The primary outcome will be the rate of stent dysfunction, and the secondary outcomes will be the duration of patency, the rate of reintervention, and the occurrence of adverse events. Discussion The aspirin for metal stents in malignant distal common bile duct obstruction (AIMS) study will determine the efficacy of aspirin in maintaining metal stent patency in patients with malignant distal CBD obstructive.

scholarly journals Aspirin for metal stent in malignant distal common bile duct obstruction (AIMS): Study protocol for a multicenter randomized controlled trial

2020 ◽  
Author(s):  
Jin Ho Choi ◽  
Woo Hyun Paik ◽  
Min Su You ◽  
Kyong Joo Lee ◽  
Young Hoon Choi ◽  
...  
Keyword(s):  
Bile Duct ◽  
Common Bile Duct ◽  
Controlled Trial ◽  
Bile Duct Obstruction ◽  
Metal Stents ◽  
Metal Stent ◽  
Stent Patency ◽  
Distal Common Bile Duct ◽  
Duct Obstruction ◽  
Common Bile Duct Obstruction

Abstract Background Endoscopic retrograde biliary drainage (ERBD) is the treatment of choice for patients with malignant distal common bile duct (CBD) obstruction. Self-expandable metal stents (SEMS), which are commonly used in unresectable cases, have many clinical advantages, including longer stent patency. Although the expected patency of SEMS is around eight months, it has recently been reported that the duration of SEMS patency in patients using aspirin is prolonged. Our study therefore aims to confirm the effect of aspirin on SEMS patency. Methods This is an investigator-initiated, prospective, multicenter, double-blind, randomized placebo-controlled trial that will be conducted from November 2017 in four tertiary centers in South Korea. We intend to include in our study 184 adult (≥ 20 years) patients with malignant distal CBD obstruction for whom ERBD with SEMS was successfully performed. The patients will be randomly allocated to two groups, which will comprise patients who have either taken 100 mg aspirin or a placebo for six months after index ERBD. The primary outcome will be the rate of stent dysfunction, and the secondary outcomes will be the duration of patency, the rate of reintervention, and the occurrence of adverse events. Discussion The aspirin for metal stents in malignant distal common bile duct obstruction (AIMS) study will determine the efficacy of aspirin in maintaining metal stent patency in patients with malignant distal CBD obstructive.

Sign in / Sign up

Export Citation Format

Share Document